Professional Experience

Scott K. Reed is the Chairman of the firm’s Litigation Practice Group.

His practice focuses on the trial and appeal of complex patent litigations for technology leaders including Bristol Myers Squibb, Genzyme, GlaxoSmithKline, Merck, Novartis, Pfizer, UCB Pharma, Emory University, Bausch & Lomb, DuPont, Mitsui, Union Carbide, Quebec Metal Powders, Canon, and IBM.

Mr. Reed has extensive trial experience and has served as lead trial counsel in cases involving pharmaceuticals, biotechnology, chemicals and electronic and computer technologies.

His patent litigations include representing: 

• Bristol-Myers Squibb in Regents of the University of Michigan and Repligen Corporation v. Bristol-Myers Squibb (fusion protein regulation of the immune system), Housey Pharmaceuticals v. Bristol-Myers Squibb (cell based biotechnology assays), Zymogenetics v. Bristol-Myers Squibb (fusion proteins) and Regents of the University of Michigan and Repligen Corporation v. Bristol-Myers (rheumatoid arthritis pharmaceuticals)
  
  
• Genzyme in Bonecare and Genzyme v. Pentech, Eagle, Sandoz, Anchen, and Roxanne (kidney disease pharmaceuticals); Bonecare and Genzyme v. Impax, Lupin, Endo, Teva, Watson, and Sandoz (kidney disease pharmaceuticals); Daiichi-Sankyo and Genzyme v. Impax and Lupin (anti-cholesterol pharmaceuticals). 
  
  
• GlaxoSmithKline in GlaxoSmithKline v. Barr  (prostate pharmaceuticals); Pozen v. Par (migrane pharmaceuticals)
  
  
• Merck in Merck v. Alcon (anti-glaucoma pharmaceuticals)
  
  
• Novartis in Novartis v. Abbott (organ transplant cyclosporin pharmaceuticals) 
  
  
• Pfizer in Pfizer v. Barr (estrogen contraceptive pharmaceuticals) and Pfizer v. Barr (hormone replacement therapy pharmaceuticals)
  
  
• UCB v. Mylan, UCB v. Dr. Reddy’s, UCB v. Ivax, UCB v. Sandoz and UCB v. Cobalt (epilepsy pharmaceuticals); UCB v. KV (attention deficit disorder pharmaceuticals)
  
  
• Emory University in Emory University v. Glaxo Wellcome (anti-hepatitis pharmaceuticals) and Emory University v. Glaxo Wellcome and BioChem Pharma (anti-AIDS pharmaceuticals)
  
  
• Bausch & Lomb in Bausch & Lomb v. Alcon and Bausch & Lomb v. Allergan (contact lens care products containing proteolytic enzymes and antimicrobial agents), Visx v. Bausch & Lomb (laser eye surgery), Allergan v. Bausch & Lomb (intraocular lenses), Allergan v. Bausch & Lomb (anti-glaucoma pharmaceuticals), Bausch & Lomb v. GNC, Bausch & Lomb v. Leiner, Bausch & Lomb v. Alcon, and Bausch & Lomb v. Rexall (nutritional supplement to treat Macular Degeneration)
  
  
• DuPont in Schneider v. DuPont and DuPont v. Cordis (polymeric balloon angioplasty materials)
  
  
• Mitsui in 3M v. Mitsui (adhesive technology)
  
  
• Union Carbide in BP v. Union Carbide (polyethylene processing technology)
  
  
• Quebec Metal Powders in Hoeganaes v. Quebec Metal Powders (powder metallurgy)
  
  
• Canon in Honeywell v. Canon (autofocus camera technology) and Gross v. Canon (microprocessor technology and optical devices)
  
  
• IBM in Berkeley v. IBM (personal computers); Valutron v. IBM (point of sale devices)
  

Mr. Reed also presently serves on the firm’s Management Committee.

Awards and Recognition

Scott K. Reed was listed in Legal 500 2007-2009 in Patent Litigation and in Legal Media Group Guide to the World’s Leading Patent Law Practitioners 2007-2009.

For information on the selection process, see:

http://www.legal500.com/index.php?option=com_content&task=view&id=772&Itemid=1

Education

J.D., Franklin Pierce Law Center, 1987, Editorial Board (IDEA) Journal of Law and Technology
B.S. Chemistry & Economics (double major), Ursinus College, 1984

Bar Admissions

State of New York, 1988; U.S. District Courts for the Southern, Eastern and Western Districts of New York; U.S. Patent and Trademark Office

Professional Activities

American Bar Association; American Intellectual Property Law Association; Federal Bar Counsel; Federal Circuit Bar Association; New York Intellectual Property Law Association